Identity
Abbott Laboratories, S.A.
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €128.0M | |
| 2025 | €79.3M | |
| 2024 | €43.9M | |
| + regional platforms | ||
| 2023 | €54.5M | |
| 2022 | €27.0M | |
| 2021 | €25.4M | |
| 2020 | €24.8M | |
| 2019 | €43.8M | |
| 2018 | €6.6M | |
| 2017 | €4.3M | |
| 2016 | €0.3M | |
In figures
Volume
Between 2016 and 2026 it won 729 contracts worth €438M on its own, with 72 buyers. Its 2 joint-venture (UTE) contracts are shown separately.
Price
In 2024–2026 its median discount was 15.3%; the middle half of its discounts between 9.1% and 23.1% (18 comparable awards).
Competition
Since 2024, 22% of its comparable value was won with a discount and against other bidders. It was the only bidder in 83% of its contracts (2016–2026).
Renewals
194 contracts (€89.8M) come up for tender again in the next 24 months.
A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Abbott Laboratories, S.A.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Abbott Laboratories, S.A.'s share.
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage
| UTE partners | Contracts | Total value (100 %) |
|---|
Its discounts
The discount at which it wins contested contracts, year by year.
2024–2026: median 15.3% · middle half between 9.1% and 23.1% · 18 awards
2017–2023: median 10.1% (43 awards) · 2024–2026: median 15.3% (18 awards).
2017–2026: median 10.3% · middle half between 4.2% and 17.1% · 61 awards
Discount on the tender budget, excluding VAT, on awards above the minor-contract threshold · Source: official data, national and regional coverage. Methodology →
Where it wins, and at what discount
In the report · these discounts, one by one
Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.
By sector
Equipamiento médico
CPV 331
108 contracts · €131M
Productos farmacéuticos
CPV 336
245 contracts · €114M
By buyer · 2024–2026
Departamento de Salud Valencia - Arnau de Vilanova - Llíria. Dirección Económica-Gerencia
Productos farmacéuticos
7 contracts · €18.7M
Gerencia de Atención Primaria del Área de Salud de Gran Canaria
Equipamiento médico
5 contracts · €11.3M
Gerencia Sector Sanitario de Zaragoza 3
Productos farmacéuticos
1 contract · €99.4k
Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.
17 awards at the tender price, left out of the discounts.
How it wins
Whether it wins with or without competition.
53% of the comparable value since 2024 (€46.1M of €86.9M) was won at the tender price and without other bidders. €21.6M (25%) was awarded with a discount and without other bidders.
Comparable: 50 awards with a published budget and bidder count (€86.9M of €251M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.
Between 2016 and 2026, 64.0% of the value was awarded through open procedure (36.9% of contracts); followed by Other (18.3%) and Negotiated without publicity (13.9%).
Upcoming tenders and main buyers
When its contracts come back and who it sells to.
In the next 24 months 194 of its contracts come up for tender again, worth €89.8M.
and 189 more in the next 24 months · the report includes them all
Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.
| Buyer | Contracts | Value, € | Period |
|---|---|---|---|
| Servicio Andaluz de Salud | 183 | 78 M | 2024–2026 |
| Servicio de Salud de las Illes Balears | 25 | 78 M | 2018–2026 |
| Departamento de Salud La Fe. Dirección Económica-Gerencia | 25 | 62 M | 2017–2026 |
| Gerencia Sector Sanitario de Zaragoza 3 | 32 | 33 M | 2018–2026 |
| Gerencia Regional de Salud de Castilla y León | 5 | 25 M | 2019–2025 |
and 67 more buyers
Between 2016 and 2026, 98.3% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 543 contracts); followed by Lab & precision instruments (CPV 38), with 1.5%.
Recent awards
The evidence behind every insight in the report.
| Date | Contract | Buyer | Bidders | Value |
|---|---|---|---|---|
| 28/09/2026 | Contrato basado AM SCS 2023/74 para el suministro de material fungible de la diabetes mellitus tipo… | Servicio Cántabro de Salud | 1 | €141k |
| 27/08/2026 | Contrato basado AM SCS 2023/74 para el suministro de material fungible de la diabetes mellitus tipo… | Servicio Cántabro de Salud | 1 | €52.7k |
| 27/07/2026 | Suministro de gafas con experiencias de realidad mixta | Fundación de Hemoterapia y Hemodonación de Castilla y León | 2 | €24.3k |
| 24/07/2026 | Contrato basado AM SCS 2023/74 para el suministro de material fungible de la diabetes mellitus tipo… | Servicio Cántabro de Salud | 1 | €39.0k |
| 24/06/2026 | Contrato basado AM SCS 2023/74 para el suministro de material fungible de la diabetes mellitus tipo… | Servicio Cántabro de Salud | 1 | €58.1k |